Return to homepagePandemic Pact

A Disruptive AntimicrobialSmart Photocatalytic Glass: A Disruptive Antimicrobial Coating for the Protection of Glass Surfaces & Designed to Tackle the Emergent Crisis of Resistant Microbes and Viruses

Grant number: 959211

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2022

  • Known Financial Commitments (USD)

    $1,898,815.88

  • Funder

    European Commission

  • Principal Investigator

    Kennedy James

  • Research Location

    Ireland

  • Lead Research Institution

    KASTUS TECHNOLOGIES LIMITED

  • Research Priority Alignment

    N/A

  • Research Category

    Infection prevention and control

  • Research Subcategory

    Barriers, PPE, environmental, animal and vector control measures

  • Special Interest Tags

    Innovation

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Kastus¬Æ is an Award-Winning surface innovation company founded in 2014 with global headquarters and manufacturing based in Ireland. Our patented range of antimicrobial (AM) and hydrophilic coatings are designed to enhance surfaces across our 2 core Industries, Glass (TRL 8) and Ceramics. In relation to the antimicrobial coatings, the technology is designed to eliminate up to 99.99% of harmful bacteria and viruses such as Corona, C. Diff, MRSA and E. Coli. Kastus¬Æ has also been funded by Atlantic Bridge (VC) to get the technology from TRL 3 to 8 and funding is now required to get to get the glass formulation to TRL 9. Kastus¬Æ needs the EIC support to accelerate the technology into full production and allow us to expand our disruptive technology offering into the entire touchscreen and glass AM sectors. We have built the momentum and the funding and support from the EIC will enable us to expand and build a global European company with forecasted revenues in 2025 of over 'Ǩ42m. Without the funding, the risk of losing first to market advantage is high due to the large cost needed to commercialise. Previous submission to SME Instrument in July 2019, Kastus¬Æ was awarded the Seal of Excellence.